The left ventricular assist devices market size has grown strongly in recent years. It will grow from $1.73 billion in 2025 to $1.9 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing prevalence of advanced heart failure, limited availability of donor hearts, expansion of specialized cardiac care centers, improvements in surgical implantation techniques, rising clinical acceptance of mechanical circulatory support.
The left ventricular assist devices market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing aging population with cardiac conditions, rising demand for long-term heart failure management solutions, advancements in biocompatible materials, growing integration of remote monitoring technologies, expanding reimbursement coverage for lvads. Major trends in the forecast period include increasing adoption of continuous flow lvads, rising use of lvads as destination therapy, growing focus on miniaturized implantable pumps, expansion of remote patient monitoring capabilities, enhanced emphasis on device durability and longevity.
The increase in healthcare expenditures is expected to drive the growth of the left ventricular assist device market in the future. Healthcare expenditures encompass all costs related to providing health services, family planning activities, nutrition programs, and emergency assistance with a focus on health. Higher healthcare spending can facilitate the advancement and development of various health-related products, including left ventricular assist devices. As healthcare expenditures rise, they will positively impact the growth of the left ventricular assist device market. For example, in June 2025, data from the Centers for Medicare & Medicaid Services (CMS), a United States-based federal agency, indicated that national health spending rose by 7.5% in 2023 to reach $4.9 trillion, representing 17.6% of the United States gross domestic product. Thus, the rise in healthcare expenditures is propelling the growth of the left ventricular assist device market.
Companies active in the left ventricular assist devices space are increasingly concentrating on the development of next-generation technologies, including wave membrane-based systems, as alternatives to conventional rotary LVADs. Wave membrane solutions are designed to mimic natural cardiac pulsatility and blood flow dynamics, closely replicating the function of a healthy heart and potentially reducing complications associated with continuous-flow devices.For instance, in September 2025, CorWave SA, a France-based medical device company, successfully performed the first human implantation of its Left Ventricular Assisting System (LVAS) at St Vincent’s Hospital in Sydney. The system delivered complete cardiac support by effectively unloading the left ventricle while maintaining an aortic pulse pressure of 25.5 ± 6.1 mmHg and enabling consistent aortic valve opening. The device met its primary study endpoints without any device-related adverse events at 30 days, and the patient subsequently underwent a successful heart transplant after 84 days of support. This development marks a significant advancement in durable mechanical circulatory support through the delivery of safe, physiological pulsatile blood flow.
In March 2025, Abbott Laboratories, a United States-based healthcare technology company, entered into a collaboration agreement with Cadrenal Therapeutics, Inc. for an undisclosed value. Through this partnership, Abbott sought to support Cadrenal in the execution of a pivotal clinical trial evaluating tecarfarin in patients implanted with HeartMate 3™ LVADs, thereby strengthening its role in advanced heart failure care and clinical research. Cadrenal Therapeutics, Inc. is a United States-based biopharmaceutical company focused on the development of novel anticoagulant therapies, including tecarfarin, specifically for patients using cardiovascular devices such as left ventricular assist devices.
Major companies operating in the left ventricular assist devices market are Abbott Laboratories, Medtronic plc, Terumo Corporation, St. Jude Medical, MAQUET GmbH & Co., LivaNova Plc, Thoratec Corporation, Abiomed Inc, Berlin Heart GmbH, BioVentrix, Cleveland Heart Inc., Jarvik Heart Inc., CorWave SA, SynCardia Systems LLC, NuPulseCV Inc., Fineheart, Procyrion Inc, Carmat SA, BiVACOR Inc, Cardiac Assist Inc., Leviticus Cardio Ltd., Calon Cardio-Technology Ltd, Evaheart Inc., Sunshine Heart Inc., CH Biomedical Inc.
North America was the largest region in the left ventricular assist devices market in 2025. The regions covered in the left ventricular assist devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the left ventricular assist devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the left ventricular assist devices market by increasing costs of imported precision components, biocompatible materials, electronic controllers, and manufacturing equipment used in implantable and transcutaneous LVAD systems. Hospitals and cardiac centers in North America and Europe are most affected due to reliance on specialized imported components, while Asia-Pacific faces higher production costs for export-oriented device manufacturing. These tariffs are increasing device pricing and procurement complexity for healthcare providers. However, they are also encouraging localized manufacturing, regional supplier partnerships, and greater investment in domestic medical device production capabilities.
The left ventricular assist devices market research report is one of a series of new reports that provides left ventricular assist devices market statistics, including left ventricular assist devices industry global market size, regional shares, competitors with a left ventricular assist devices market share, detailed left ventricular assist devices market segments, market trends and opportunities, and any further data you may need to thrive in the left ventricular assist devices industry. This left ventricular assist devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A left ventricular assist device (LVAD) serves as a mechanical pump implanted in heart failure patients, assisting the heart's lower left chamber (left ventricle) in pumping blood to the aorta and throughout the body.
The primary types of left ventricular assist devices include transcutaneous left ventricular assist devices and implantable left ventricular assist devices. A transcutaneous left ventricular assist device is characterized by having both an external power supply and an internal pump located inside the body. Tubes connect the pump to the heart through small openings in the abdomen. This type of LVAD is often employed for short-term support during or following surgery. Left ventricular assist devices can have either pulsatile or non-pulsatile flows, and they are used in various therapeutic approaches such as bridge-to-recovery (BTR) therapy, bridge-to-transplant (BTT) therapy, destination therapy, and bridge-to-candidacy (BTC) therapy. Cardiology centers and hospitals typically utilize these devices for patient care.
The left ventricular assist devices market consists of sales of rechargeable left ventricular assist devices, non-rechargeable left ventricular assist devices, heart pumps, and controllers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The left ventricular assist devices market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing aging population with cardiac conditions, rising demand for long-term heart failure management solutions, advancements in biocompatible materials, growing integration of remote monitoring technologies, expanding reimbursement coverage for lvads. Major trends in the forecast period include increasing adoption of continuous flow lvads, rising use of lvads as destination therapy, growing focus on miniaturized implantable pumps, expansion of remote patient monitoring capabilities, enhanced emphasis on device durability and longevity.
The increase in healthcare expenditures is expected to drive the growth of the left ventricular assist device market in the future. Healthcare expenditures encompass all costs related to providing health services, family planning activities, nutrition programs, and emergency assistance with a focus on health. Higher healthcare spending can facilitate the advancement and development of various health-related products, including left ventricular assist devices. As healthcare expenditures rise, they will positively impact the growth of the left ventricular assist device market. For example, in June 2025, data from the Centers for Medicare & Medicaid Services (CMS), a United States-based federal agency, indicated that national health spending rose by 7.5% in 2023 to reach $4.9 trillion, representing 17.6% of the United States gross domestic product. Thus, the rise in healthcare expenditures is propelling the growth of the left ventricular assist device market.
Companies active in the left ventricular assist devices space are increasingly concentrating on the development of next-generation technologies, including wave membrane-based systems, as alternatives to conventional rotary LVADs. Wave membrane solutions are designed to mimic natural cardiac pulsatility and blood flow dynamics, closely replicating the function of a healthy heart and potentially reducing complications associated with continuous-flow devices.For instance, in September 2025, CorWave SA, a France-based medical device company, successfully performed the first human implantation of its Left Ventricular Assisting System (LVAS) at St Vincent’s Hospital in Sydney. The system delivered complete cardiac support by effectively unloading the left ventricle while maintaining an aortic pulse pressure of 25.5 ± 6.1 mmHg and enabling consistent aortic valve opening. The device met its primary study endpoints without any device-related adverse events at 30 days, and the patient subsequently underwent a successful heart transplant after 84 days of support. This development marks a significant advancement in durable mechanical circulatory support through the delivery of safe, physiological pulsatile blood flow.
In March 2025, Abbott Laboratories, a United States-based healthcare technology company, entered into a collaboration agreement with Cadrenal Therapeutics, Inc. for an undisclosed value. Through this partnership, Abbott sought to support Cadrenal in the execution of a pivotal clinical trial evaluating tecarfarin in patients implanted with HeartMate 3™ LVADs, thereby strengthening its role in advanced heart failure care and clinical research. Cadrenal Therapeutics, Inc. is a United States-based biopharmaceutical company focused on the development of novel anticoagulant therapies, including tecarfarin, specifically for patients using cardiovascular devices such as left ventricular assist devices.
Major companies operating in the left ventricular assist devices market are Abbott Laboratories, Medtronic plc, Terumo Corporation, St. Jude Medical, MAQUET GmbH & Co., LivaNova Plc, Thoratec Corporation, Abiomed Inc, Berlin Heart GmbH, BioVentrix, Cleveland Heart Inc., Jarvik Heart Inc., CorWave SA, SynCardia Systems LLC, NuPulseCV Inc., Fineheart, Procyrion Inc, Carmat SA, BiVACOR Inc, Cardiac Assist Inc., Leviticus Cardio Ltd., Calon Cardio-Technology Ltd, Evaheart Inc., Sunshine Heart Inc., CH Biomedical Inc.
North America was the largest region in the left ventricular assist devices market in 2025. The regions covered in the left ventricular assist devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the left ventricular assist devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the left ventricular assist devices market by increasing costs of imported precision components, biocompatible materials, electronic controllers, and manufacturing equipment used in implantable and transcutaneous LVAD systems. Hospitals and cardiac centers in North America and Europe are most affected due to reliance on specialized imported components, while Asia-Pacific faces higher production costs for export-oriented device manufacturing. These tariffs are increasing device pricing and procurement complexity for healthcare providers. However, they are also encouraging localized manufacturing, regional supplier partnerships, and greater investment in domestic medical device production capabilities.
The left ventricular assist devices market research report is one of a series of new reports that provides left ventricular assist devices market statistics, including left ventricular assist devices industry global market size, regional shares, competitors with a left ventricular assist devices market share, detailed left ventricular assist devices market segments, market trends and opportunities, and any further data you may need to thrive in the left ventricular assist devices industry. This left ventricular assist devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A left ventricular assist device (LVAD) serves as a mechanical pump implanted in heart failure patients, assisting the heart's lower left chamber (left ventricle) in pumping blood to the aorta and throughout the body.
The primary types of left ventricular assist devices include transcutaneous left ventricular assist devices and implantable left ventricular assist devices. A transcutaneous left ventricular assist device is characterized by having both an external power supply and an internal pump located inside the body. Tubes connect the pump to the heart through small openings in the abdomen. This type of LVAD is often employed for short-term support during or following surgery. Left ventricular assist devices can have either pulsatile or non-pulsatile flows, and they are used in various therapeutic approaches such as bridge-to-recovery (BTR) therapy, bridge-to-transplant (BTT) therapy, destination therapy, and bridge-to-candidacy (BTC) therapy. Cardiology centers and hospitals typically utilize these devices for patient care.
The left ventricular assist devices market consists of sales of rechargeable left ventricular assist devices, non-rechargeable left ventricular assist devices, heart pumps, and controllers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Left Ventricular Assist Devices Market Characteristics
3. Left Ventricular Assist Devices Market Supply Chain Analysis
4. Global Left Ventricular Assist Devices Market Trends and Strategies
5. Left Ventricular Assist Devices Market Analysis of End Use Industries
7. Global Left Ventricular Assist Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Left Ventricular Assist Devices Total Addressable Market (TAM) Analysis for the Market
9. Left Ventricular Assist Devices Market Segmentation
10. Left Ventricular Assist Devices Market Regional and Country Analysis
11. Asia-Pacific Left Ventricular Assist Devices Market
12. China Left Ventricular Assist Devices Market
13. India Left Ventricular Assist Devices Market
14. Japan Left Ventricular Assist Devices Market
15. Australia Left Ventricular Assist Devices Market
16. Indonesia Left Ventricular Assist Devices Market
17. South Korea Left Ventricular Assist Devices Market
18. Taiwan Left Ventricular Assist Devices Market
19. South East Asia Left Ventricular Assist Devices Market
20. Western Europe Left Ventricular Assist Devices Market
21. UK Left Ventricular Assist Devices Market
22. Germany Left Ventricular Assist Devices Market
23. France Left Ventricular Assist Devices Market
24. Italy Left Ventricular Assist Devices Market
25. Spain Left Ventricular Assist Devices Market
26. Eastern Europe Left Ventricular Assist Devices Market
27. Russia Left Ventricular Assist Devices Market
28. North America Left Ventricular Assist Devices Market
29. USA Left Ventricular Assist Devices Market
30. Canada Left Ventricular Assist Devices Market
31. South America Left Ventricular Assist Devices Market
32. Brazil Left Ventricular Assist Devices Market
33. Middle East Left Ventricular Assist Devices Market
34. Africa Left Ventricular Assist Devices Market
36. Left Ventricular Assist Devices Market Competitive Landscape and Company Profiles
37. Left Ventricular Assist Devices Market Other Major and Innovative Companies
40. Left Ventricular Assist Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Left Ventricular Assist Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses left ventricular assist devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for left ventricular assist devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The left ventricular assist devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Percutaneous Left Ventricular Assist Devices; Implantable Left Ventricular Assist Devices2) By Type Of Flow: Pulsatile; Non-Pulsatile
3) By Application: Bridge-To-Recovery (BTR) Therapy; Bridge-To-Transplant (BTT) Therapy; Destination Therapy; Bridge-To-Candidacy (BTC) Therapy
4) By End-User: Cardiology Centers; Hospitals
Subsegments:
1) By Percutaneous Left Ventricular Assist Devices: Axial-Flow Percutaneous LVADs; Centrifugal-Flow Percutaneous LVADs2) By Implantable Left Ventricular Assist Devices: Continuous Flow Devices; Pulsatile Flow Devices
Companies Mentioned: Abbott Laboratories; Medtronic plc; Terumo Corporation; St. Jude Medical; MAQUET GmbH & Co.; LivaNova Plc; Thoratec Corporation; Abiomed Inc; Berlin Heart GmbH; BioVentrix; Cleveland Heart Inc.; Jarvik Heart Inc.; CorWave SA; SynCardia Systems LLC; NuPulseCV Inc.; Fineheart; Procyrion Inc; Carmat SA; BiVACOR Inc; Cardiac Assist Inc.; Leviticus Cardio Ltd.; Calon Cardio-Technology Ltd; Evaheart Inc.; Sunshine Heart Inc.; CH Biomedical Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Left Ventricular Assist Devices market report include:- Abbott Laboratories
- Medtronic plc
- Terumo Corporation
- St. Jude Medical
- MAQUET GmbH & Co.
- LivaNova Plc
- Thoratec Corporation
- Abiomed Inc
- Berlin Heart GmbH
- BioVentrix
- Cleveland Heart Inc.
- Jarvik Heart Inc.
- CorWave SA
- SynCardia Systems LLC
- NuPulseCV Inc.
- Fineheart
- Procyrion Inc
- Carmat SA
- BiVACOR Inc
- Cardiac Assist Inc.
- Leviticus Cardio Ltd.
- Calon Cardio-Technology Ltd
- Evaheart Inc.
- Sunshine Heart Inc.
- CH Biomedical Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.9 Billion |
| Forecasted Market Value ( USD | $ 2.78 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
